{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:58:14Z","timestamp":1791597494952,"version":"4.3.4"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mitochondrial diseases, caused by mutations in either mitochondrial or nuclear DNA, are highly complex genetic disorders characterized by faulty oxidative phosphorylation. Adeno-associated virus (AAV)-based gene therapy with its broad and customizable tissue tropism achieved through natural and engineered serotypes offers a highly effective platform for delivering therapeutic genes to affected tissues. However, the intricate genetics and biology of mitochondria present unique challenges for the development of AAV-based therapies. While gene replacement therapy remains a viable strategy for correcting nuclear gene defects, mutations in mtDNA require specialized approaches, such as mitochondrially targeted, RNA-free base editors and nucleases capable of precise editing within the mitochondrial genome. As an alternative, allotopic expression, which involves expressing mitochondrial genes from the nuclear genome, is currently being evaluated in clinical trials but remains controversial, due to issues related to mitochondrial import and functional integration in the respiratory complexes. The clinical translation of AAV-mediated therapies for mitochondrial diseases still confronts several interrelated challenges, including efficient targeting of multiple affected organs, scalable and cost-effective vector manufacturing, and minimizing vector-associated toxicity. By integrating advanced genome editing technologies with sophisticated vector engineering and delivery strategies, AAV-based gene therapy stands as a transformative approach for addressing the broad and heterogeneous spectrum of primary mitochondrial disorders. Continued progress in overcoming current biological and technical barriers will be essential to realize the full therapeutic potential of AAVs.<\/jats:p>","DOI":"10.1038\/s41380-026-03570-y","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:21:16Z","timestamp":1777447276000},"page":"4882-4894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adeno-Associated virus-based approaches for mitochondrial diseases: advances and challenges"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1985-6194","authenticated-orcid":false,"given":"Samantha","family":"Corr\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Balmaceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-0566","authenticated-orcid":false,"given":"Carlo","family":"Viscomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"3570_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-024-02044-3","volume":"10","author":"H Wen","year":"2025","unstructured":"Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X, et al. Mitochondrial diseases: from molecular mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025;10:9.","journal-title":"Signal Transduct Target Ther"},{"key":"3570_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41580-021-00415-0","volume":"23","author":"I Vercellino","year":"2022","unstructured":"Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nat Rev Mol Cell Biol. 2022;23:141\u201361.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3570_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/jb\/mvr049","volume":"149","author":"D Okuno","year":"2011","unstructured":"Okuno D, Iino R, Noji H. Rotation and structure of FoF1-ATP synthase. J Biochem. 2011;149:655\u201364.","journal-title":"J Biochem"},{"key":"3570_CR4","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1126\/science.286.5445.1700","volume":"286","author":"D Stock","year":"1999","unstructured":"Stock D, Leslie AGW, Walker JE. Molecular architecture of the rotary motor in ATP Synthase. Science. 1999;286:1700\u20135.","journal-title":"Science"},{"key":"3570_CR5","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.cell.2024.04.037","volume":"187","author":"A Suomalainen","year":"2024","unstructured":"Suomalainen A, Nunnari J. Mitochondria at the crossroads of health and disease. Cell. 2024;187:2601\u201327.","journal-title":"Cell"},{"key":"3570_CR6","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/1873-3468.14068","volume":"595","author":"M Gusic","year":"2021","unstructured":"Gusic M, Prokisch H. Genetic basis of mitochondrial diseases. FEBS Lett. 2021;595:1132\u201358.","journal-title":"FEBS Lett"},{"key":"3570_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/348651a0","volume":"348","author":"Y Goto","year":"1990","unstructured":"Goto Y, Nonaka I, Horai S. A mutation in the tRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348:651\u20133.","journal-title":"Nature"},{"key":"3570_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJM198905183202001","volume":"320","author":"CT Moraes","year":"1989","unstructured":"Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and kearns-sayre syndrome. N Engl J Med. 1989;320:1293\u20139.","journal-title":"N Engl J Med"},{"key":"3570_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1086\/518301","volume":"48","author":"C Hayden","year":"2007","unstructured":"Hayden C. A generic solution?: pharmaceuticals and the politics of the similar in Mexico. Curr Anthropol. 2007;48:475\u201395.","journal-title":"Curr Anthropol"},{"key":"3570_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/290457a0","volume":"290","author":"S Anderson","year":"1981","unstructured":"Anderson S, Bankier AT, Barrell BG, De Bruijn MHL, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290:457\u201365.","journal-title":"Nature"},{"key":"3570_CR11","doi-asserted-by":"publisher","first-page":"D1541","DOI":"10.1093\/nar\/gkaa1011","volume":"49","author":"S Rath","year":"2021","unstructured":"Rath S, Sharma R, Gupta R, Ast T, Chan C, Durham TJ, et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 2021;49:D1541\u201347.","journal-title":"Nucleic Acids Res"},{"key":"3570_CR12","doi-asserted-by":"crossref","unstructured":"Leigh syndrome. Handb Clin Neurol, vol. 194, Elsevier; 2023. p. 43\u201363.","DOI":"10.1016\/B978-0-12-821751-1.00015-4"},{"key":"3570_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1086\/302150","volume":"63","author":"V Tiranti","year":"1998","unstructured":"Tiranti V, Hoertnagel K, Carrozzo R, Galimberti C, Munaro M, Granatiero M, et al. Mutations of SURF-1 in leigh disease associated with cytochrome c oxidase deficiency. Am J Hum Genet. 1998;63:1609\u201321.","journal-title":"Am J Hum Genet"},{"key":"3570_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(89)92897-3","volume":"333","author":"A Rotig","year":"1989","unstructured":"Rotig A, Colonna M, Bonnefont JP, Blanche S, Fischer A, Saudubray JM, et al. mitochondrial dna deletion in pearson\u2019s marrow\/pancreas syndrome. Lancet. 1989;333:902\u20133.","journal-title":"Lancet"},{"key":"3570_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/0092-8674(90)90059-N","volume":"61","author":"JM Shoffner","year":"1990","unstructured":"Shoffner JM, Lott MT, Lezza AMS, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation. Cell. 1990;61:931\u20137.","journal-title":"Cell"},{"key":"3570_CR16","first-page":"428","volume":"46","author":"IJ Holt","year":"1990","unstructured":"Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet. 1990;46:428\u201333.","journal-title":"Am J Hum Genet"},{"key":"3570_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1055\/s-0037-1603776","volume":"48","author":"S Wortmann","year":"2017","unstructured":"Wortmann S, Mayr J, Nuoffer J, Prokisch H, Sperl W. A guideline for the diagnosis of pediatric mitochondrial disease: the value of muscle and skin biopsies in the genetics era. Neuropediatrics. 2017;48:309\u201314.","journal-title":"Neuropediatrics"},{"key":"3570_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-015-9823-y","volume":"38","author":"SB Wortmann","year":"2015","unstructured":"Wortmann SB, Koolen DA, Smeitink JA, Den Van Heuvel L, Rodenburg RJ. Whole exome sequencing of suspected mitochondrial patients in clinical practice. J Inherit Metab Dis. 2015;38:437\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"3570_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/ng.706","volume":"42","author":"TB Haack","year":"2010","unstructured":"Haack TB, Danhauser K, Haberberger B, Hoser J, Strecker V, Boehm D, et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet. 2010;42:1131\u20134.","journal-title":"Nat Genet"},{"key":"3570_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/humu.22307","volume":"34","author":"S Tang","year":"2013","unstructured":"Tang S, Wang J, Zhang VW, Li F-Y, Landsverk M, Cui H, et al. Transition to next generation analysis of the whole mitochondrial genome: a summary of molecular defects. Hum Mutat. 2013;34:882\u201393.","journal-title":"Hum Mutat"},{"key":"3570_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2024.100770","volume":"48","author":"N-C Tsai","year":"2025","unstructured":"Tsai N-C, Liou C-W, Cheng Y-H, Lien H-T, Lin T-L, Lin T-K, et al. The establishment of a molecular diagnostic platform for mitochondrial diseases: From conventional to next-generation sequencing. Biomed J. 2025;48:100770.","journal-title":"Biomed J"},{"key":"3570_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jimd.12663","volume":"46","author":"D Smirnov","year":"2023","unstructured":"Smirnov D, Konstantinovskiy N, Prokisch H. Integrative omics approaches to advance rare disease diagnostics. J Inherit Metab Dis. 2023;46:824\u201338.","journal-title":"J Inherit Metab Dis"},{"key":"3570_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","volume":"9","author":"Y Zong","year":"2024","unstructured":"Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:124.","journal-title":"Signal Transduct Target Ther"},{"key":"3570_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"3570_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, et al. Long-Term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994\u20132004.","journal-title":"N Engl J Med"},{"key":"3570_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu Z-F, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","journal-title":"Lancet"},{"key":"3570_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1126\/science.149.3685.754","volume":"149","author":"RW Atchison","year":"1965","unstructured":"Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated defective virus particles. Science. 1965;149:754\u20136.","journal-title":"Science"},{"key":"3570_CR28","doi-asserted-by":"crossref","unstructured":"Mezzina M, Merten O-W Adeno-Associated Viruses. In: Merten O-W, Al-Rubeai M, editors. Viral Vectors Gene Ther. Totowa, NJ: Humana Press; 2011. 737, pp. 211-34.","DOI":"10.1007\/978-1-61779-095-9_9"},{"key":"3570_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","volume":"59","author":"K Erles","year":"1999","unstructured":"Erles K, Seb\u00f6kov\u00e0 P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999;59:406\u201311.","journal-title":"J Med Virol"},{"key":"3570_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno\u2010associated viruses. J Infect Dis. 2009;199:381\u201390.","journal-title":"J Infect Dis"},{"key":"3570_CR31","doi-asserted-by":"crossref","unstructured":"Berns KI, Giraud C. Biology of Adeno-associated Virus. In: Berns KI, Giraud C, editors. Adeno-Assoc. Virus AAV Vectors Gene Ther., Berlin, Heidelberg: Springer Berlin Heidelberg. 1996. 218, pp. 1\u201323.","DOI":"10.1007\/978-3-642-80207-2_1"},{"key":"3570_CR32","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/mt.2014.99","volume":"22","author":"C Hu","year":"2014","unstructured":"Hu C, Kasten J, Park H, Bhargava R, Tai DS, Grody WW, et al. Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice. Mol Ther. 2014;22:1792\u2013802.","journal-title":"Mol Ther"},{"key":"3570_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/jgm.1249","volume":"10","author":"H Kuroda","year":"2008","unstructured":"Kuroda H, Kutner RH, Bazan NG, Reiser J. A comparative analysis of constitutive and cell\u2010specific promoters in the adult mouse hippocampus using lentivirus vector\u2010mediated gene transfer. J Gene Med. 2008;10:1163\u201375.","journal-title":"J Gene Med"},{"key":"3570_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1479-0556-6-13","volume":"6","author":"CA Pacak","year":"2008","unstructured":"Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther. 2008;6:13.","journal-title":"Genet Vaccines Ther"},{"key":"3570_CR35","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","volume":"10","author":"DM McCarty","year":"2003","unstructured":"McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 2003;10:2112\u20138.","journal-title":"Gene Ther"},{"key":"3570_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1099\/vir.0.18726-0","volume":"84","author":"D H\u00fcser","year":"2003","unstructured":"H\u00fcser D, Heilbronn R. Adeno-associated virus integrates site-specifically into human chromosome 19 in either orientation and with equal kinetics and frequency. J Gen Virol. 2003;84:133\u20137.","journal-title":"J Gen Virol"},{"key":"3570_CR37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","volume":"42","author":"JA Greig","year":"2024","unstructured":"Greig JA, Martins KM, Breton C, Lamontagne RJ, Zhu Y, He Z, et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat Biotechnol. 2024;42:1232\u201342.","journal-title":"Nat Biotechnol"},{"key":"3570_CR38","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/mt.2013.92","volume":"21","author":"Z Yan","year":"2013","unstructured":"Yan Z, Keiser NW, Song Y, Deng X, Cheng F, Qiu J, et al. A novel chimeric adenoassociated virus 2\/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia. Mol Ther. 2013;21:2181\u201394.","journal-title":"Mol Ther"},{"key":"3570_CR39","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/brain\/awh259","volume":"127","author":"M Zeviani","year":"2004","unstructured":"Zeviani M. Mitochondrial disorders. Brain. 2004;127:2153\u201372.","journal-title":"Brain"},{"key":"3570_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jimd.12699","volume":"47","author":"N Keshavan","year":"2024","unstructured":"Keshavan N, Minczuk M, Viscomi C, Rahman S. Gene therapy for mitochondrial disorders. J Inherit Metab Dis. 2024;47:145\u201375.","journal-title":"J Inherit Metab Dis"},{"key":"3570_CR41","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.bbabio.2016.02.012","volume":"1857","author":"RJ Rodenburg","year":"2016","unstructured":"Rodenburg RJ. Mitochondrial complex I-linked disease. Biochim Biophys Acta BBA - Bioenerg. 2016;1857:938\u201345.","journal-title":"Biochim Biophys Acta BBA - Bioenerg"},{"key":"3570_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2020.148335","volume":"1862","author":"M Brischigliaro","year":"2021","unstructured":"Brischigliaro M, Zeviani M. Cytochrome c oxidase deficiency. Biochim Biophys Acta BBA - Bioenerg. 2021;1862:148335.","journal-title":"Biochim Biophys Acta BBA - Bioenerg"},{"key":"3570_CR43","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910674","volume":"12","author":"CV Pereira","year":"2020","unstructured":"Pereira CV, Peralta S, Arguello T, Bacman SR, Diaz F, Moraes CT. Myopathy reversion in mice after restauration of mitochondrial complex I. EMBO Mol Med. 2020;12:e10674.","journal-title":"EMBO Mol Med"},{"key":"3570_CR44","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu W-L, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20:1172\u20139.","journal-title":"Nat Neurosci"},{"key":"3570_CR45","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/s44321-024-00111-4","volume":"16","author":"BR Walker","year":"2024","unstructured":"Walker BR, Theard L-M, Pinto M, Rodriguez-Silva M, Bacman SR, Moraes CT. Restoration of defective oxidative phosphorylation to a subset of neurons prevents mitochondrial encephalopathy. EMBO Mol Med. 2024;16:2210\u201332.","journal-title":"EMBO Mol Med"},{"key":"3570_CR46","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cmet.2008.02.004","volume":"7","author":"SE Kruse","year":"2008","unstructured":"Kruse SE, Watt WC, Marcinek DJ, Kapur RP, Schenkman KA, Palmiter RD. Mice with mitochondrial complex i deficiency develop a fatal encephalomyopathy. Cell Metab. 2008;7:312\u201320.","journal-title":"Cell Metab"},{"key":"3570_CR47","doi-asserted-by":"publisher","first-page":"10996","DOI":"10.1073\/pnas.1006214107","volume":"107","author":"A Quintana","year":"2010","unstructured":"Quintana A, Kruse SE, Kapur RP, Sanz E, Palmiter RD. Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. Proc Natl Acad Sci. 2010;107:10996\u20131001.","journal-title":"Proc Natl Acad Sci"},{"key":"3570_CR48","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/brain\/awaa105","volume":"143","author":"R Reynaud-Dulaurier","year":"2020","unstructured":"Reynaud-Dulaurier R, Benegiamo G, Marrocco E, Al-Tannir R, Surace EM, Auwerx J, et al. Gene replacement therapy provides benefit in an adult mouse model of Leigh syndrome. Brain. 2020;143:1686\u201396.","journal-title":"Brain"},{"key":"3570_CR49","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.omtm.2020.04.026","volume":"17","author":"P Silva-Pinheiro","year":"2020","unstructured":"Silva-Pinheiro P, Cerutti R, Luna-Sanchez M, Zeviani M, Viscomi C. A single intravenous injection of AAV-PHP.B-hNDUFS4 ameliorates the phenotype of Ndufs4 Mice. Mol Ther - Methods Clin Dev. 2020;17:1071\u20138.","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"3570_CR50","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/gt.2017.53","volume":"24","author":"I Di Meo","year":"2017","unstructured":"Di Meo I, Marchet S, Lamperti C, Zeviani M, Viscomi C. AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome. Gene Ther. 2017;24:661\u20137.","journal-title":"Gene Ther"},{"key":"3570_CR51","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1093\/brain\/awac182","volume":"145","author":"S Corr\u00e0","year":"2022","unstructured":"Corr\u00e0 S, Cerutti R, Balmaceda V, Viscomi C, Zeviani M. Double administration of self-complementary AAV9 NDUFS4 prevents Leigh disease in Ndufs4 \u2212\/\u2212 mice. Brain. 2022;145:3405\u201314.","journal-title":"Brain"},{"key":"3570_CR52","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","volume":"27","author":"J Hordeaux","year":"2019","unstructured":"Hordeaux J, Yuan Y, Clark PM, Wang Q, Martino RA, Sims JJ, et al. The GPI-Linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol Ther. 2019;27:912\u201321.","journal-title":"Mol Ther"},{"key":"3570_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/hum.2019.186","volume":"31","author":"Batista","year":"2020","unstructured":"Batista AR, King OD, Reardon CP, Davis C, Shankaracharya, Philip V, et al. Ly6a Differential expression in blood\u2013brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B. Hum Gene Ther. 2020;31:90\u2013102.","journal-title":"Hum Gene Ther"},{"key":"3570_CR54","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/hmg\/ddl477","volume":"16","author":"C Dell\u2019Agnello","year":"2007","unstructured":"Dell\u2019Agnello C, Leo S, Agostino A, Szabadkai G, Tiveron C, Zulian A, et al. Increased longevity and refractoriness to Ca2+-dependent neurodegeneration in Surf1 knockout mice. Hum Mol Genet. 2007;16:431\u201344.","journal-title":"Hum Mol Genet"},{"key":"3570_CR55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omtm.2021.09.001","volume":"23","author":"Q Ling","year":"2021","unstructured":"Ling Q, Rioux M, Hu Y, Lee M, Gray SJ. Adeno-associated viral vector serotype 9-based gene replacement therapy for SURF1-related Leigh syndrome. Mol Ther - Methods Clin Dev. 2021;23:158\u201368.","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"3570_CR56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1086\/381653","volume":"74","author":"V Tiranti","year":"2004","unstructured":"Tiranti V, D\u2019Adamo P, Briem E, Ferrari G, Mineri R, Lamantea E, et al. Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet. 2004;74:239\u201352.","journal-title":"Am J Hum Genet"},{"key":"3570_CR57","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nm.1907","volume":"15","author":"V Tiranti","year":"2009","unstructured":"Tiranti V, Viscomi C, Hildebrandt T, Di Meo I, Mineri R, Tiveron C, et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med. 2009;15:200\u20135.","journal-title":"Nat Med"},{"key":"3570_CR58","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/emmm.201201433","volume":"4","author":"I Di Meo","year":"2012","unstructured":"Di Meo I, Auricchio A, Lamperti C, Burlina A, Viscomi C, Zeviani M. Effective AAV\u2010mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol Med. 2012;4:1008\u201314.","journal-title":"EMBO Mol Med"},{"key":"3570_CR59","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.15252\/emmm.201505040","volume":"7","author":"I Di Meo","year":"2015","unstructured":"Di Meo I, Lamperti C, Tiranti V. Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches. EMBO Mol Med. 2015;7:1257\u201366.","journal-title":"EMBO Mol Med"},{"key":"3570_CR60","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s13311-013-0177-6","volume":"10","author":"AW El-Hattab","year":"2013","unstructured":"El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics. 2013;10:186\u201398.","journal-title":"Neurotherapeutics"},{"key":"3570_CR61","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/ng1765","volume":"38","author":"A Spinazzola","year":"2006","unstructured":"Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F, D\u2019Adamo P, Calvo S, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet. 2006;38:570\u20135.","journal-title":"Nat Genet"},{"key":"3570_CR62","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1086\/506913","volume":"79","author":"CL Karadimas","year":"2006","unstructured":"Karadimas CL, Vu TH, Holve SA, Chronopoulou P, Quinzii C, Johnsen SD, et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 Gene. Am J Hum Genet. 2006;79:544\u20138.","journal-title":"Am J Hum Genet"},{"key":"3570_CR63","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.nmd.2012.03.006","volume":"22","author":"EL Blakely","year":"2012","unstructured":"Blakely EL, Butterworth A, Hadden RDM, Bodi I, He L, McFarland R, et al. MPV17 mutation causes neuropathy and leukoencephalopathy with multiple mtDNA deletions in muscle. Neuromuscul Disord. 2012;22:587\u201391.","journal-title":"Neuromuscul Disord"},{"key":"3570_CR64","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cge.13462","volume":"95","author":"M Baumann","year":"2019","unstructured":"Baumann M, Schreiber H, Schlotter\u2010Weigel B, L\u00f6scher WN, Stucka R, Karall D, et al. MPV17 mutations in juvenile\u2010 and adult\u2010onset axonal sensorimotor polyneuropathy. Clin Genet. 2019;95:182\u20136.","journal-title":"Clin Genet"},{"key":"3570_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107955","volume":"26","author":"S Corr\u00e0","year":"2023","unstructured":"Corr\u00e0 S, Checchetto V, Brischigliaro M, Rampazzo C, Bottani E, Gagliani C, et al. Drosophila Mpv17 forms an ion channel and regulates energy metabolism. iScience. 2023;26:107955.","journal-title":"iScience"},{"key":"3570_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/hmg\/ddn309","volume":"18","author":"C Viscomi","year":"2009","unstructured":"Viscomi C, Spinazzola A, Maggioni M, Fernandez-Vizarra E, Massa V, Pagano C, et al. Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice. Hum Mol Genet. 2009;18:12\u201326.","journal-title":"Hum Mol Genet"},{"key":"3570_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/mt.2013.230","volume":"22","author":"E Bottani","year":"2014","unstructured":"Bottani E, Giordano C, Civiletto G, Di Meo I, Auricchio A, Ciusani E, et al. AAV-mediated Liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure. Mol Ther. 2014;22:10\u201317.","journal-title":"Mol Ther"},{"key":"3570_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ng746","volume":"29","author":"H Mandel","year":"2001","unstructured":"Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet. 2001;29:337\u201341.","journal-title":"Nat Genet"},{"key":"3570_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108554","volume":"143","author":"N Keshavan","year":"2024","unstructured":"Keshavan N, Rahman S. Natural history of deoxyguanosine kinase deficiency. Mol Genet Metab. 2024;143:108554.","journal-title":"Mol Genet Metab"},{"key":"3570_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101397","volume":"33","author":"N Keshavan","year":"2025","unstructured":"Keshavan N, Greenwood M, Prunty H, Diaz JA, Privolizzi R, Counsell J, et al. Gene therapy prevents hepatic mitochondrial dysfunction in murine deoxyguanosine kinase deficiency. Mol Ther Methods Clin Dev. 2025;33:101397.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3570_CR71","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.283.5402.689","volume":"283","author":"I Nishino","year":"1999","unstructured":"Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in mngie, a human mitochondrial disorder. Science. 1999;283:689\u201392.","journal-title":"Science"},{"key":"3570_CR72","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/gt.2011.24","volume":"18","author":"J Torres-Torronteras","year":"2011","unstructured":"Torres-Torronteras J, G\u00f3mez A, Eixarch H, Palenzuela L, Pizzorno G, Hirano M, et al. Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther. 2011;18:795\u2013806.","journal-title":"Gene Ther"},{"key":"3570_CR73","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/mt.2014.6","volume":"22","author":"J Torres-Torronteras","year":"2014","unstructured":"Torres-Torronteras J, Viscomi C, Cabrera-P\u00e9rez R, C\u00e1mara Y, Di Meo I, Barquinero J, et al. Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. Mol Ther. 2014;22:901\u20137.","journal-title":"Mol Ther"},{"key":"3570_CR74","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1089\/hum.2017.133","volume":"29","author":"J Torres-Torronteras","year":"2018","unstructured":"Torres-Torronteras J, Cabrera-P\u00e9rez R, Vila-Juli\u00e0 F, Viscomi C, C\u00e1mara Y, Hirano M, et al. Long-Term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther. 2018;29:708\u201318.","journal-title":"Hum Gene Ther"},{"key":"3570_CR75","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1089\/hum.2018.217","volume":"30","author":"R Cabrera-P\u00e9rez","year":"2019","unstructured":"Cabrera-P\u00e9rez R, Vila-Juli\u00e0 F, Hirano M, Mingozzi F, Torres-Torronteras J, Mart\u00ed R. Alpha-1-antitrypsin promoter improves the efficacy of an adeno-associated virus vector for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther. 2019;30:985\u201398.","journal-title":"Hum Gene Ther"},{"key":"3570_CR76","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1089\/hum.2021.152","volume":"32","author":"M Par\u00e9s","year":"2021","unstructured":"Par\u00e9s M, Fornaguera C, Vila-Juli\u00e0 F, Oh S, Fan SHY, Tam YK, et al. Preclinical assessment of a gene-editing approach in a mouse model of mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther. 2021;32:1210\u201323.","journal-title":"Hum Gene Ther"},{"key":"3570_CR77","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/ng751","volume":"29","author":"A Saada","year":"2001","unstructured":"Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet. 2001;29:342\u20134.","journal-title":"Nat Genet"},{"key":"3570_CR78","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ana.26185","volume":"90","author":"C Lopez\u2010Gomez","year":"2021","unstructured":"Lopez\u2010Gomez C, Sanchez\u2010Quintero MJ, Lee EJ, Kleiner G, Tadesse S, Xie J, et al. Synergistic deoxynucleoside and gene therapies for thymidine kinase 2 deficiency. Ann Neurol. 2021;90:640\u201352.","journal-title":"Ann Neurol"},{"key":"3570_CR79","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1126\/science.289.5480.782","volume":"289","author":"J Kaukonen","year":"2000","unstructured":"Kaukonen J, Juselius JK, Tiranti V, Kytt\u00e4l\u00e4 A, Zeviani M, Comi GP, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000;289:782\u20135.","journal-title":"Science"},{"key":"3570_CR80","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/sj.gt.3302443","volume":"12","author":"A Flierl","year":"2005","unstructured":"Flierl A, Chen Y, Coskun PE, Samulski RJ, Wallace DC. Adeno-associated virus-mediated gene transfer of the heart\/muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther. 2005;12:570\u20138.","journal-title":"Gene Ther"},{"key":"3570_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100975","volume":"86","author":"C Botto","year":"2022","unstructured":"Botto C, Rucli M, Tekinsoy MD, Pulman J, Sahel J-A, Dalkara D. Early and late stage gene therapy interventions for inherited retinal degenerations. Prog Retin Eye Res. 2022;86:100975.","journal-title":"Prog Retin Eye Res"},{"key":"3570_CR82","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/brain\/awq288","volume":"134","author":"P Yu-Wai-Man","year":"2011","unstructured":"Yu-Wai-Man P, Trenell MI, Hollingsworth KG, Griffiths PG, Chinnery PF. OPA1 mutations impair mitochondrial function in both pure and complicated dominant optic atrophy. Brain. 2011;134:e164\u2013e164.","journal-title":"Brain"},{"key":"3570_CR83","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/79936","volume":"26","author":"C Delettre","year":"2000","unstructured":"Delettre C, Lenaers G, Griffoin J-M, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26:207\u201310.","journal-title":"Nat Genet"},{"key":"3570_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20838-8","volume":"8","author":"E Sarzi","year":"2018","unstructured":"Sarzi E, Seveno M, Piro-M\u00e9gy C, Elzi\u00e8re L, Quil\u00e8s M, P\u00e9quignot M, et al. OPA1 gene therapy prevents retinal ganglion cell loss in a dominant optic atrophy mouse model. Sci Rep. 2018;8:2468.","journal-title":"Sci Rep"},{"key":"3570_CR85","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature01034","volume":"419","author":"JA Klein","year":"2002","unstructured":"Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 2002;419:367\u201374.","journal-title":"Nature"},{"key":"3570_CR86","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/brain\/awr290","volume":"135","author":"A Bouaita","year":"2012","unstructured":"Bouaita A, Augustin S, Lechauve C, Cwerman-Thibault H, B\u00e9nit P, Simonutti M, et al. Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy. Brain. 2012;135:35\u201352.","journal-title":"Brain"},{"key":"3570_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105483","volume":"159","author":"H Cwerman-Thibault","year":"2021","unstructured":"Cwerman-Thibault H, Lechauve C, Malko-Baverel V, Augustin S, Le Guilloux G, Reboussin \u00c9, et al. Neuroglobin effectively halts vision loss in Harlequin mice at an advanced stage of optic nerve degeneration. Neurobiol Dis. 2021;159:105483.","journal-title":"Neurobiol Dis"},{"key":"3570_CR88","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ymthe.2024.05.030","volume":"32","author":"H Cwerman-Thibault","year":"2024","unstructured":"Cwerman-Thibault H, Malko-Baverel V, Le Guilloux G, Ratcliffe E, Mouri D, Torres-Cuevas I, et al. Neuroglobin overexpression in cerebellar neurons of Harlequin mice improves mitochondrial homeostasis and reduces ataxic behavior. Mol Ther. 2024;32:2150\u201375.","journal-title":"Mol Ther"},{"key":"3570_CR89","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano V, Montermini L, Molt\u00f2 MD, Pianese L, Coss\u00e9e M, Cavalcanti F, et al. Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423\u20137.","journal-title":"Science"},{"key":"3570_CR90","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/84818","volume":"27","author":"H Puccio","year":"2001","unstructured":"Puccio H, Simon D, Coss\u00e9e M, Criqui-Filipe P, Tiziano F, Melki J, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. 2001;27:181\u20136.","journal-title":"Nat Genet"},{"key":"3570_CR91","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","volume":"20","author":"M Perdomini","year":"2014","unstructured":"Perdomini M, Belbellaa B, Monassier L, Reutenauer L, Messaddeq N, Cartier N, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia. Nat Med. 2014;20:542\u20137.","journal-title":"Nat Med"},{"key":"3570_CR92","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","volume":"19","author":"B Belbellaa","year":"2020","unstructured":"Belbellaa B, Reutenauer L, Messaddeq N, Monassier L, Puccio H. High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol Ther - Methods Clin Dev. 2020;19:120\u201338.","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"3570_CR93","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","volume":"26","author":"F Piguet","year":"2018","unstructured":"Piguet F, De Montigny C, Vaucamps N, Reutenauer L, Eisenmann A, Puccio H. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of friedreich ataxia. Mol Ther. 2018;26:1940\u201352.","journal-title":"Mol Ther"},{"key":"3570_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02324-7","volume":"17","author":"AR Hanaford","year":"2022","unstructured":"Hanaford AR, Cho Y-J, Nakai H. AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives. Orphanet J Rare Dis. 2022;17:217.","journal-title":"Orphanet J Rare Dis"},{"key":"3570_CR95","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/hmg\/ddy072","volume":"27","author":"Y Peng","year":"2018","unstructured":"Peng Y, Shinde DN, Alexander Valencia C, Mo J-S, Rosenfeld J, Cho MT, et al. Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Hum Mol Genet. 2018;27:2224.","journal-title":"Hum Mol Genet"},{"key":"3570_CR96","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.omtm.2020.05.021","volume":"18","author":"L Yang","year":"2020","unstructured":"Yang L, Slone J, Zou W, Queme LF, Jankowski MP, Yin F, et al. Systemic Delivery of AAV-Fdxr mitigates the phenotypes of mitochondrial disorders in Fdxr Mutant Mice. Mol Ther - Methods Clin Dev. 2020;18:84\u201397.","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"3570_CR97","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/ng0496-385","volume":"12","author":"S Bione","year":"1996","unstructured":"Bione S, D\u2019Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet. 1996;12:385\u20139.","journal-title":"Nat Genet"},{"key":"3570_CR98","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/hum.2018.020","volume":"30","author":"S Suzuki-Hatano","year":"2019","unstructured":"Suzuki-Hatano S, Saha M, Rizzo SA, Witko RL, Gosiker BJ, Ramanathan M, et al. AAV-Mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in barth syndrome. Hum Gene Ther. 2019;30:139\u201354.","journal-title":"Hum Gene Ther"},{"key":"3570_CR99","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/CIRCRESAHA.119.315956","volume":"126","author":"S Wang","year":"2020","unstructured":"Wang S, Li Y, Xu Y, Ma Q, Lin Z, Schlame M, et al. AAV gene therapy prevents and reverses heart failure in a murine knockout model of barth syndrome. Circ Res. 2020;126:1024\u201339.","journal-title":"Circ Res"},{"key":"3570_CR100","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.15252\/emmm.201506159","volume":"8","author":"A Janer","year":"2016","unstructured":"Janer A, Prudent J, Paupe V, Fahiminiya S, Majewski J, Sgarioto N, et al. SLC 25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol Med. 2016;8:1019\u201338.","journal-title":"EMBO Mol Med"},{"key":"3570_CR101","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/hmg\/ddz277","volume":"29","author":"L Yang","year":"2020","unstructured":"Yang L, Slone J, Li Z, Lou X, Hu Y-C, Queme LF, et al. Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46\u2212\/\u2212 mice. Hum Mol Genet. 2020;29:649\u201361.","journal-title":"Hum Mol Genet"},{"key":"3570_CR102","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2741\/4529","volume":"22","author":"CT Moraes","year":"2017","unstructured":"Moraes CT. Current strategies towards therapeutic manipulation of mtDNA heteroplasmy. Front Biosci. 2017;22:991\u20131010.","journal-title":"Front Biosci"},{"key":"3570_CR103","doi-asserted-by":"crossref","unstructured":"Bacman SR, Williams SL, Pinto M, Moraes CT The use of mitochondria-targeted endonucleases to manipulate mtDNA. Methods Enzymol., vol. 547, Elsevier; 2014. pp. 373\u201397.","DOI":"10.1016\/B978-0-12-801415-8.00018-7"},{"key":"3570_CR104","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s10439-022-03051-7","volume":"52","author":"N Mikhailov","year":"2024","unstructured":"Mikhailov N, H\u00e4m\u00e4l\u00e4inen RH. Modulating mitochondrial DNA heteroplasmy with mitochondrially targeted endonucleases. Ann Biomed Eng. 2024;52:2627\u201340.","journal-title":"Ann Biomed Eng"},{"key":"3570_CR105","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.gendis.2019.08.001","volume":"7","author":"IM Artika","year":"2020","unstructured":"Artika IM. Allotopic expression of mitochondrial genes: basic strategy and progress. Genes Dis. 2020;7:578\u201384.","journal-title":"Genes Dis"},{"key":"3570_CR106","doi-asserted-by":"publisher","first-page":"14392","DOI":"10.1073\/pnas.0502896102","volume":"102","author":"MP Bayona-Bafaluy","year":"2005","unstructured":"Bayona-Bafaluy MP, Blits B, Battersby BJ, Shoubridge EA, Moraes CT. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc Natl Acad Sci. 2005;102:14392\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"3570_CR107","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/gt.2008.11","volume":"15","author":"MF Alexeyev","year":"2008","unstructured":"Alexeyev MF, Venediktova N, Pastukh V, Shokolenko I, Bonilla G, Wilson GL. Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes. Gene Ther. 2008;15:516\u201323.","journal-title":"Gene Ther"},{"key":"3570_CR108","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41591-018-0165-9","volume":"24","author":"PA Gammage","year":"2018","unstructured":"Gammage PA, Viscomi C, Simard M-L, Costa ASH, Gaude E, Powell CA, et al. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. Nat Med. 2018;24:1691\u20135.","journal-title":"Nat Med"},{"key":"3570_CR109","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/emmm.201303672","volume":"6","author":"PA Gammage","year":"2014","unstructured":"Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M. Mitochondrially targeted ZFN s for selective degradation of pathogenic mitochondrial genomes bearing large\u2010scale deletions or point mutations. EMBO Mol Med. 2014;6:458\u201366.","journal-title":"EMBO Mol Med"},{"key":"3570_CR110","doi-asserted-by":"crossref","unstructured":"Bacman SR, Kauppila JHK, Pereira CV, Nissanka N, Miranda M, Pinto M, Williams SL, Larsson NG, Stewart JB, Moraes CT. MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation. Nat Med. 2018;24:1696\u2013700.","DOI":"10.1038\/s41591-018-0166-8"},{"key":"3570_CR111","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s13238-017-0499-y","volume":"9","author":"Y Yang","year":"2018","unstructured":"Yang Y, Wu H, Kang X, Liang Y, Lan T, Li T, et al. Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs. Protein Cell. 2018;9:283\u201397.","journal-title":"Protein Cell"},{"key":"3570_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102132","volume":"35","author":"SR Bacman","year":"2024","unstructured":"Bacman SR, Barrera-Paez JD, Pinto M, Van Booven D, Stewart JB, Griswold AJ, et al. mitoTALEN reduces the mutant mtDNA load in neurons. Mol Ther - Nucleic Acids. 2024;35:102132.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"3570_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23561-7","volume":"12","author":"U Zekonyte","year":"2021","unstructured":"Zekonyte U, Bacman SR, Smith J, Shoop W, Pereira CV, Tomberlin G, et al. Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo. Nat Commun. 2021;12:3210.","journal-title":"Nat Commun"},{"key":"3570_CR114","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jmb.2005.10.065","volume":"355","author":"S Arnould","year":"2006","unstructured":"Arnould S, Chames P, Perez C, Lacroix E, Duclert A, Epinat J-C, et al. Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol. 2006;355:443\u201358.","journal-title":"J Mol Biol"},{"key":"3570_CR115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/protein\/gzq083","volume":"24","author":"S Arnould","year":"2011","unstructured":"Arnould S, Delenda C, Grizot S, Desseaux C, Paques F, Silva GH, et al. The I-CreI meganuclease and its engineered derivatives: applications from cell modification to gene therapy. Protein Eng Des Sel. 2011;24:27\u201331.","journal-title":"Protein Eng Des Sel"},{"key":"3570_CR116","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/s42255-023-00932-6","volume":"5","author":"WK Shoop","year":"2023","unstructured":"Shoop WK, Lape J, Trum M, Powell A, Sevigny E, Mischler A, et al. Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease. Nat Metab. 2023;5:2169\u201383.","journal-title":"Nat Metab"},{"key":"3570_CR117","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s12276-023-00973-7","volume":"55","author":"HTL Phan","year":"2023","unstructured":"Phan HTL, Lee H, Kim K. Trends and prospects in mitochondrial genome editing. Exp Mol Med. 2023;55:871\u20138.","journal-title":"Exp Mol Med"},{"key":"3570_CR118","doi-asserted-by":"publisher","first-page":"R92","DOI":"10.1093\/hmg\/ddae037","volume":"33","author":"CT Moraes","year":"2024","unstructured":"Moraes CT. Tools for editing the mammalian mitochondrial genome. Hum Mol Genet. 2024;33:R92\u2013R99.","journal-title":"Hum Mol Genet"},{"key":"3570_CR119","doi-asserted-by":"publisher","DOI":"10.17863\/CAM.82379","volume":"13","author":"P Silva-Pinheiro","year":"2022","unstructured":"Silva-Pinheiro P, Nash PA, Van Haute L, Mutti CD, Turner K, Minczuk M. In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue. Nat Commun. 2022;13:750. https:\/\/doi.org\/10.17863\/CAM.82379.","journal-title":"Nat Commun"},{"key":"3570_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21464-1","volume":"12","author":"H Lee","year":"2021","unstructured":"Lee H, Lee S, Baek G, Kim A, Kang B-C, Seo H, et al. Mitochondrial DNA editing in mice with DddA-TALE fusion deaminases. Nat Commun. 2021;12:1190.","journal-title":"Nat Commun"},{"key":"3570_CR121","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr0792","volume":"17","author":"JD Barrera-Paez","year":"2025","unstructured":"Barrera-Paez JD, Bacman SR, Balla T, Van Booven D, Gannamedi DP, Stewart JB, et al. Correcting a pathogenic mitochondrial DNA mutation by base editing in mice. Sci Transl Med. 2025;17:eadr0792.","journal-title":"Sci Transl Med"},{"key":"3570_CR122","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41587-022-01486-w","volume":"41","author":"S Lee","year":"2023","unstructured":"Lee S, Lee H, Baek G, Kim J-S. Precision mitochondrial DNA editing with high-fidelity DddA-derived base editors. Nat Biotechnol. 2023;41:378\u201386.","journal-title":"Nat Biotechnol"},{"key":"3570_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66600-3","volume":"16","author":"S Kim","year":"2025","unstructured":"Kim S, Kim J, Cha S, Ju S, Lim CJ, Hong S, et al. In vivo mitochondrial base editing restores genotype and visual function in a mouse model of LHON. Nat Commun. 2025;16:10923.","journal-title":"Nat Commun"},{"key":"3570_CR124","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.cell.2022.03.039","volume":"185","author":"S-I Cho","year":"2022","unstructured":"Cho S-I, Lee S, Mok YG, Lim K, Lee J, Lee JM, et al. Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases. Cell. 2022;185:1764\u201376.e12.","journal-title":"Cell"},{"key":"3570_CR125","doi-asserted-by":"publisher","unstructured":"Mutti CD, Van Haute L, Luengo-Gutierrez L, Turner K, Silva-Pinheiro P, Minczuk M Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery. 2025. https:\/\/doi.org\/10.7554\/eLife.105080.1.","DOI":"10.7554\/eLife.105080.1"},{"key":"3570_CR126","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41587-023-01791-y","volume":"42","author":"Z Yi","year":"2024","unstructured":"Yi Z, Zhang X, Tang W, Yu Y, Wei X, Zhang X, et al. Strand-selective base editing of human mitochondrial DNA using mitoBEs. Nat Biotechnol. 2024;42:498\u2013509.","journal-title":"Nat Biotechnol"},{"key":"3570_CR127","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41587-025-02608-w","volume":"44","author":"Y Fan","year":"2025","unstructured":"Fan Y, Xu W, Gao B-Q, Qin H, Wu X, Wei J, et al. Leveraging base excision repair for efficient adenine base editing of mitochondrial DNA. Nat Biotechnol. 2025;44:277\u201390. https:\/\/doi.org\/10.1038\/s41587-025-02608-w.","journal-title":"Nat Biotechnol"},{"key":"3570_CR128","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41586-024-08469-8","volume":"639","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang X, Ren J, Li J, Wei X, Yu Y, et al. Precise modelling of mitochondrial diseases using optimized mitoBEs. Nature. 2025;639:735\u201345.","journal-title":"Nature"},{"key":"3570_CR129","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41587-025-02685-x","volume":"44","author":"L Chen","year":"2025","unstructured":"Chen L, Hong M, Luan C, Yuan M, Wang Y, Guo X, et al. Efficient mitochondrial A-to-G base editors for the generation of mitochondrial disease models. Nat Biotechnol. 2025;44:418\u201329. https:\/\/doi.org\/10.1038\/s41587-025-02685-x.","journal-title":"Nat Biotechnol"},{"key":"3570_CR130","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.mito.2023.09.004","volume":"73","author":"F Nieto-Panqueva","year":"2023","unstructured":"Nieto-Panqueva F, Rubalcava-Gracia D, Hamel PP, Gonz\u00e1lez-Halphen D. The constraints of allotopic expression. Mitochondrion. 2023;73:30\u201350.","journal-title":"Mitochondrion"},{"key":"3570_CR131","doi-asserted-by":"crossref","unstructured":"Oca-Cossio J, Kenyon L, Hao H, Moraes CT. Limitations of allotopic expression of mitochondrial genes in mammalian cells. Genetics. 2003;165:707\u201320.","DOI":"10.1093\/genetics\/165.2.707"},{"key":"3570_CR132","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamaophthalmol.2013.7630","volume":"132","author":"RD Koilkonda","year":"2014","unstructured":"Koilkonda RD, Yu H, Chou T-H, Feuer WJ, Ruggeri M, Porciatti V, et al. Safety and effects of the vector for the leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol. 2014;132:409.","journal-title":"JAMA Ophthalmol"},{"key":"3570_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.3","volume":"2","author":"H Cwerman-Thibault","year":"2015","unstructured":"Cwerman-Thibault H, Augustin S, Lechauve C, Ayache J, Ellouze S, Sahel J-A, et al. Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss. Mol Ther - Methods Clin Dev. 2015;2:15003.","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"3570_CR134","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/nar\/gkq769","volume":"39","author":"E Perales-Clemente","year":"2011","unstructured":"Perales-Clemente E, Fern\u00e1ndez-Silva P, Ac\u00edn-P\u00e9rez R, P\u00e9rez-Martos A, Enr\u00edquez JA. Allotopic expression of mitochondrial-encoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task? Nucleic Acids Res. 2011;39:225\u201334.","journal-title":"Nucleic Acids Res"},{"key":"3570_CR135","doi-asserted-by":"publisher","first-page":"14210","DOI":"10.1074\/jbc.273.23.14210","volume":"273","author":"A Barrientos","year":"1998","unstructured":"Barrientos A, Kenyon L, Moraes CT. Human xenomitochondrial cybrids. J Biol Chem. 1998;273:14210\u20137.","journal-title":"J Biol Chem"},{"key":"3570_CR136","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","volume":"128","author":"NJ Newman","year":"2021","unstructured":"Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, et al. Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology. 2021;128:649\u201360.","journal-title":"Ophthalmology"},{"key":"3570_CR137","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz7423","volume":"12","author":"P Yu-Wai-Man","year":"2020","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020;12:eaaz7423.","journal-title":"Sci Transl Med"},{"key":"3570_CR138","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/WNO.0000000000001367","volume":"41","author":"V Biousse","year":"2021","unstructured":"Biousse V, Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Vignal-Clermont C, et al. Long-Term follow-up after unilateral intravitreal gene therapy for leber hereditary optic neuropathy: the RESTORE study. J Neuroophthalmol. 2021;41:309\u201315.","journal-title":"J Neuroophthalmol"},{"key":"3570_CR139","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/d41573-023-00067-z","volume":"22","author":"C Viscomi","year":"2023","unstructured":"Viscomi C, Van Den Ameele J, Meyer KC, Chinnery PF. Opportunities for mitochondrial disease gene therapy. Nat Rev Drug Discov. 2023;22:429\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"3570_CR140","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","volume":"22","author":"Q Ling","year":"2023","unstructured":"Ling Q, Herstine JA, Bradbury A, Gray SJ. AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov. 2023;22:789\u2013806.","journal-title":"Nat Rev Drug Discov"},{"key":"3570_CR141","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41551-022-00938-7","volume":"6","author":"Y Yao","year":"2022","unstructured":"Yao Y, Wang J, Liu Y, Qu Y, Wang K, Zhang Y, et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood\u2013brain barrier in rodents and primates. Nat Biomed Eng. 2022;6:1257\u201371.","journal-title":"Nat Biomed Eng"},{"key":"3570_CR142","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41592-020-0799-7","volume":"17","author":"S Ravindra Kumar","year":"2020","unstructured":"Ravindra Kumar S, Miles TF, Chen X, Brown D, Dobreva T, Huang Q, et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nat Methods. 2020;17:541\u201350.","journal-title":"Nat Methods"},{"key":"3570_CR143","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"D Goertsen","year":"2022","unstructured":"Goertsen D, Flytzanis NC, Goeden N, Chuapoco MR, Cummins A, Chen Y, et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat Neurosci. 2022;25:106\u201315.","journal-title":"Nat Neurosci"},{"key":"3570_CR144","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.neuron.2022.05.003","volume":"110","author":"X Chen","year":"2022","unstructured":"Chen X, Ravindra Kumar S, Adams CD, Yang D, Wang T, Wolfe DA, et al. Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems. Neuron. 2022;110:2242\u201357.e6.","journal-title":"Neuron"},{"key":"3570_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03893-z","volume":"20","author":"Q Zhao","year":"2025","unstructured":"Zhao Q, Peng H, Ma Y, Yuan H, Jiang H. In vivo applications and toxicities of AAV-based gene therapies in rare diseases. Orphanet J Rare Dis. 2025;20:368.","journal-title":"Orphanet J Rare Dis"},{"key":"3570_CR146","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29:464\u201388.","journal-title":"Mol Ther"},{"key":"3570_CR147","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1016\/j.cell.2025.06.026","volume":"188","author":"BP Dhungel","year":"2025","unstructured":"Dhungel BP, Xu H, Nagarajah R, Vitale J, Wong ACH, Gokal D, et al. An alternate receptor for adeno-associated viruses. Cell. 2025;188:4924\u201335.e23.","journal-title":"Cell"},{"key":"3570_CR148","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.ymthe.2025.03.065","volume":"33","author":"NE Bengtsson","year":"2025","unstructured":"Bengtsson NE, Tasfaout H, Chamberlain JS. The road toward AAV-mediated gene therapy of duchenne muscular dystrophy. Mol Ther. 2025;33:2035\u201351.","journal-title":"Mol Ther"},{"key":"3570_CR149","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1126\/science.adp8179","volume":"386","author":"SR Lindley","year":"2024","unstructured":"Lindley SR, Subbaiah KCV, Priyanka F, Poosala P, Ma Y, Jalinous L, et al. Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies. Science. 2024;386:762\u20137.","journal-title":"Science"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03570-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03570-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:06:27Z","timestamp":1785942387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03570-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":149,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3570"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03570-y","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declare no competing interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Ethics"}}]}}